HFpEF
Advertisement
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of all heart failure diagnoses.1 ...
Empagliflozin, a sodium glucose co-transporter 2 inhibitor (SGLT2i), significantly reduced the composite endpoint of ...
Systematic evaluation should be used to increase the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), which ...
Vascular stiffness may play a larger role in heart failure than previously thought. Patients with heart failure with ...
Heart failure with preserved ejection fraction (HFpEF) is a remarkably heterogenous syndrome with multiple different ...
The 2019 Heart Failure Society of America Scientific Meeting (HFSA 2019) in Philadelphia has wrapped up. DocWire News ...
An oral potassium binding polymer (patiromer) aided in the use of spironolactone in a subset of patients with heart ...
Age was a factor in spironolactone-related adverse events in older patients with heart failure with preserved ejection ...
The PARAGON-HF trial, evaluating the safety and efficacy of sacubitril/valsartan versus valsartan alone in patients with ...
While the use of evidence-based drug therapy for heart failure (HF) is high, there are still areas for improvement, a ...
A new analysis provides encouraging data for patients with heart failure (HF) with ≥40% ejection fraction requiring ...
Coronary microvascular dysfunction (CMD) was prevalent in patients with heart failure with preserved ejection fraction ...
INDIE-HFpEF: Novel Inhaled Medication Ineffective for Heart Failure with Preserved Ejection Fraction
A month-long treatment regimen with a novel inhaled inorganic nitrate yielded no significant improvement in exercise ...Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.